Peptide Drug Conjugates and Their Role in Cancer Therapy
International Journal of Molecular Sciences · 03.01.2023 · 24 (1) · 829
DOI: 10.3390/ijms24010829 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.01.2023. Verfasst von Ethan Heh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Paul L. Foster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Immunoconjugates, Cell-Penetrating Peptides. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug conjugates have become a significant focus of research in the field of targeted medicine for cancer treatments. Peptide-drug conjugates (PDCs), a subset of drug conjugates, are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and linkers that connect the payload to the peptide. PDCs are further broken down into cell-penetrating peptides (CPPs) and cell-targeting peptides (CTPs), each having their own differences in the delivery of cytotoxic payloads. Generally, PDCs as compared to other drug conjugates—like antibody-drug conjugates (ADCs)—have advantages in tumor penetration, ease of synthesis and cost, and reduced off-target effects. Further, as compared to traditional cancer treatments (e.g., chemotherapy and radiation), PDCs have higher specificity for the target cancer with generally less toxic side effects in smaller doses. However, PDCs can have disadvantages such as poor stability and rapid renal clearance due to their smaller size and limited oral bioavailability due to digestion of its peptide structure. Some of these challenges can be overcome with modifications, and despite drawbacks, the intrinsic small size of PDCs with high target specificity still makes them an attractive area of research for cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paul L. Foster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
ORCID-Profile: Ethan Heh, Jesse Allen, Fabiola Ramirez, Daniel Lovasz, Lorena Fernandez, Nathan Holland, Jessica Chacon
Zitieren
APA
Heh, E., Allen, J., Ramirez, F., Lovasz, D., Fernandez, L., Hogg, T., Riva, H., Holland, N., & Chacon, J. (2023). Peptide Drug Conjugates and Their Role in Cancer Therapy. International Journal of Molecular Sciences, 24(1), 829. https://doi.org/10.3390/ijms24010829
Vancouver
Heh E, Allen J, Ramirez F, Lovasz D, Fernandez L, Hogg T, et al. Peptide Drug Conjugates and Their Role in Cancer Therapy. International Journal of Molecular Sciences. 2023;24(1):829. doi:10.3390/ijms24010829
BibTeX
@article{Heh2023,
author = {Heh, Ethan and Allen, Jesse and Ramirez, Fabiola and Lovasz, Daniel and Fernandez, Lorena and Hogg, Tanis and Riva, Hannah and Holland, Nathan and Chacon, Jessica},
title = {Peptide Drug Conjugates and Their Role in Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {1},
pages = {829},
doi = {10.3390/ijms24010829}
}
EUVIMED